Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a quadrivalent recombinant norovirus vaccine in children aged 6 weeks to 13 years
CTR20242628Phase 3Active
- Sponsor
- Anhui Zhifei Longcom Biopharmaceutical
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent recombinant norovirus vaccine (Pichia pastoris) in acute gastroenteritis, Noroviral gastroenteritis, sponsored by Anhui Zhifei Longcom Biopharmaceutical. Started Jul 2024; status: active.
02
Drugs
quadrivalent recombinant norovirus vaccine (Pichia pastoris)
03
Conditions
acute gastroenteritisNoroviral gastroenteritis
Beyond the preview
Go deeper on CTR20242628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242628.